Retatrutide acts as a triple agonist for GLP-1, GIP, and glucagon receptors, under investigation in obesity and metabolic disorder models. Research explores its multifaceted effects on energy expenditure, appetite regulation, and fat metabolism, with phase 2 trials in non-diabetic obesity models showing potential for substantial weight reduction and improvements in liver fat content. It is studied for insights into multi-receptor signaling in metabolic homeostasis and tissue repair.
For research use only.
